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The intestinal community, including the commensal microbial flora as well as the host tissues, represents a functional whole
in vivo. Under physiological circumstances, this symbiosis brings great benefit for the host; however, critical illness induces
profound disturbances in the intestinal ecosystem aﬀecting both procaryotic and eucaryotic members. Today, 25 years after the
gut was first described as a motor of multiple organ dysfunction syndrome, the role of the injured splanchnic compartment in the
pathomechanism and development of critical illness is still in the first line of research. Multiple mechanisms have been identified
by which the stressed gut may aﬀect host homeostasis, and how external intervention might help to rebalance physiology. This
paper provides a brief overview of the present of this field.
1. Introduction
The gastrointestinal system represents an enormous surface
to the internal world of the gut microbiome and nutrient
antigens. Mucosal immunity faces the challenge to establish
a balance between tolerance and immunity, elimination of
pathogenic microbes and preservation of the crucial cooper-
ation with normal flora members. Furthermore, commensal
enteral bacteria share many epitopes with self-structures,
making the situation even more complex, as revealed by
recent investigations [1, 2]. The intestinal microbiome,
tightly interacting with the mucosal immune network,
may be considered together as a special organ that has a
clear impact on host physiology and pathology, including
autoimmunity, atopic disorders, and even obesity [3–8].
The splanchnic immune apparatus also has an impact on
host-pathogen interactions. B-1 lymphocyte-derived natural
autoantibodies were shown to be involved in the first-line
defence against pathogens, as well as in the early T-cell
recruitment during initiation of delayed type hypersensitiv-
ity (DTH) responses [1]. The intestinal modulation of host
homeostasis becomes, however, evenmore obvious in critical
illness (definitive or imminent organ failure).
The intestinal community with both eucaryotic and
procaryotic members is partially separated from the systemic
compartment and represents an unique symbiosis, which
is recently being discovered in details. Since the majority
of commensal species is not culturable under conventional
circumstances [9], their exact nature yet remains obscure
despite intensive research. Faced with the enormous amount
of bacteria and nutrient antigens, the mucosal immune
network consists of the intestinal epithelium, intraepithelial
lymphocytes, and the immune apparatus of the lamina
propria, Peyer’s patches, and mesenteric lymph nodes. Lym-
phoid elements of the splanchnic immune system frequently
belong to unconventional lymphocyte populations that
possess a restricted repertoire and often show self-reactivity
[1]. The close proximity of these cells and intestinal antigens
2 ISRN Immunology
is, however, turned safe via multiple barriers and regulatory
ways. As for nondangerous antigens that cross the intestinal
barrier, there are numerous mechanisms that avoid local
or systemic immunization. For example, TCRγδ+ intestinal
intraepithelial lymphocytes secrete keratinocyte growth fac-
tor at the sites of mucosal injury, which helps to restore the
epithelial layer. In turn, the intact epithelial cells are involved
in the priming of CD8+ TCRγδ+ regulatory T cells that
secrete relevant amounts of IL-10 and mediate significant
anti-inflammatory eﬀect [1]. The fine spatial organization of
the intestinal network is also noticeable under physiological
circumstances. Obata et al. have discovered intratissue
colonization of the intestinal mucosa by commensal bacteria,
which does not show accidentality, but rather a strict spacial
structure under physiological circumstances [10]. In amouse
model, the surface of Peyer’s patches (PP) is mainly (98%)
colonized by segmented filamentous bacteria while the
bacterial composition of PP interior consists of Alcaligenes
spp. (72%), Ochrobactrum spp. (10%), Serratia spp. (6%),
Burkholderia spp. (4%), and a minor percentage of others.
Undiscriminated species were present throughout the surface
layer of the lamina propria. The bacterial composition of
dendritic cells (DCs) in Peyer’s patches and mesenteric
lymph nodes was also diﬀerent with Alcaligenes spp. dom-
inating in the former and Pseudomonas spp. dominating in
the latter case in mice. The ability of Alcaligenes to colonize
human and nonhuman primate (monkey) Peyer’s patches
was also shown [10]. Besides intestinal microbes, members
of the mucosal immune apparatus as well have a strictly
determined niche to live. A distinct pattern of intestinal
intraepithelial lymphocyte (iIEL) populations in diﬀerent
regions of the gut was shown to be present both in human
and rodents [11–13]. The activation and homing properties
of peritoneal B-1 lymphocytes are also strictly regulated
[1]. Intestinal dendritic cells, which are able to hold live
commensal bacteria for several days, are as well retained to
a well-determined niche via mesenteric lymph nodes, that
function as a filter for these cells as shown by a mouse model
[14]. This way, the mucosal immune responses are kept
partially separated from the systemic compartment, allowing
local IgA production but avoiding inadequate immunization
with enteral bacteria and potential consequent enterocolitis
or autoimmune complications.
Commensal bacteria as well form an active part of the
intestinal community. Besides the production of vitamin K
[15], these microbes help to digest complex carbohydrates,
thus allowing access to short-chain fatty acids (SCFAs), that
serve as nutrients for intestinal epithelial cells beyond regu-
lating their diﬀerentiation and growth [9, 16]. Microbes also
induce the production of intestinal mucus [17, 18]. In the
colon, mucus consists of two layers, of which the inner one
is densely packed, adhering to the epithelium and physically
preventing penetration of bacteria, as demonstrated on a
mouse model [19]. Beyond its barrier function, intestinal
mucus is believed to shape the composition of the microbial
flora via oﬀering special adhesion epitopes [9]. Gut bacteria
also play a crutial role in the regulation of mucosal immune
responses. Molecules recognizing the intestinal microflora
are diverse, including numerous pathways like Toll-like
receptors (TLRs), formylated peptide receptors (FPRs),
nucleotide binding oligomerization-like receptors (NODs),
IL-1β-converting enzyme protease activator factor (IPAF),
and C-type lectins with corresponding signal transduction
routes. Inflammatory and proapoptotic responses go hand
in hand, where NF-κB plays a key role. Many commensal
species limit NF-κB-dependent signalling and induce the
production of TGF-β, mediating anti-inflammatory and
antiapoptotic eﬀects [9]. Certain members of the gut
microflora were also reported to shape the Treg/TH17 balance
in the mucosa and induce immunity against intestinal
pathogens via a TH17-dependent response in mice. TH17
cells represent a special population of CD4+ T lymphocytes,
which produce IL-17, IL-17F, as well as IL-22, and play a
role in inflammatory responses against bacterial and fungal
pathogens. Molecular details of the induction of TH17 cells
are recently being discovered [20–22].
Considering the fine organization of the intestinal
mucosal tissues, the huge amount of potentially dangerous
microbes and the vulnerable balance between inflammation
and tolerance as well as symbiosis and bacterial invasivity,
the role of mucosal immunity in the pathomechanism of
critical illness is most comprehensible. The gut as a motor
of systemic inflammation (either of an infective origin or
not) and multiple organ failure was first described in the
80s, when an impaired intestinal barrier function along with
bacterial translocation in an already immunocompromised
host was believed to play a pivotal role [23, 24]. Since then,
the growing number of experimental data has refined our
knowledge; however, the majority of these come from animal
models, eminently rodents, which needs to be taken into
account. This review provides a short overview of the field.
2. Changes in the Intestinal Environment in
Critical Illness
2.1. Physiological Regulation of the Intestinal Environment.
Under physiological circumstances, the composition of the
intestinal microbial flora is strictly controlled by mucosal
tissues as well as the microbes themselves, which is crutial
for the maintenance of a healthy symbiosis. Molecular
mechanisms involved in this process are highly diverse and go
far beyond the secretion of IgA antibodies. Angiogenin 4, an
antibacterial peptide secreted by Paneth cells, is induced by
commensal organisms and it is believed to help to maintain
the Gram-negative predominance in the gut via its anti-
Gram-positive spectrum [24, 25]. Similarly, RegIIIγ, another
antibacterial agent, is induced by the microbes themselves
[26]. Defensins possessing both direct antibacterial and
immunomodulatory potential, along with broad-spectrum
antimicrobial product cryptdins also contribute to shaping
the composition of the intestinal microflora. Intermicrobial
interactions, special adhesion epitopes present on mucin
proteins as well as the presence of fucosylated glycans
(serving as nutrient for some microbes) were also shown
to have an eﬀect on the gut microbiome [9, 27]. Another
mechanism involves a special population of T lymphocytes
that modulate the NOD2-dependent activation of epithelial
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cells in response to bacterial peptidoglycans, as demonstrated
by a mouse model. These CD3+CD11c+ T cells express
PGLYRP-2 that destroys the NOD2-recognising epitope of
peptidoglycans, which is preserved by enteral lyzozime.
PGLYRP-2 positive cells belong to a mixed TCRαβ+/TCRγδ+
population, express B220 and CD69 activation markers
and reduce NOD2-mediated epithelial cell activation via
PGLYRP-2. This eﬀect was reported to aﬀect the composition
of the commensal flora [28]. The maintenance of the physio-
logical intestinal environment is also dependent on a hetero-
geneous population of regulatory T lymphocytes, including
CD4+, CD8+, as well as TCRγδ+ cells, that are engaged
with the ability to suppress immunity against nondanger-
ous intestinal antigens. Intestinal epithelial cells along with
dendritic cells of the lamina propria and mesenteric lymph
nodes are involved in the priming of regulatory lymphocytes
[1]. A healthy microbiome, in turn, induces a tolerogenic,
antiapoptotic milieu, regulates its own composition, pro-
vides access to otherwise inaccessible nutrient factors (e.g.,
short-chain fatty acids), and suppresses pathogenic species.
2.2. Alteration of the Intestinal Microenvironment in Crit-
ical Illness. In life-threatening states, there are numerous
factors contributing to the pathological alteration of the
intestinal microbial community [29]. Systemic antibiotics,
splanchnic ischemia-reperfusion, mucosal acidosis, impaired
production of mucins, and appearance of bacterial deriva-
tives in the blood along with the lack of local nutrients
(either as a consequence of total parenteral nutrition or
highly processed enteral nutrients resulting in distal bowel
nutrient deficiency) may occur and contribute to enhanced
apoptosis, histological disorganization of the mucosa, and
change of the intestinal microbial composition. The above-
mentioned regulatory ways which shape the gut microbiome
are impaired in injured mucosal tissues, which is augmented
by the pathological shift in the microflora itself.
Many widely used broad-spectrum antibiotics were
reported to have a profound eﬀect on the composition of
the intestinal microbial community even in healthy human
volunteers. Intravenously (i.v.) administered cefoperazone
dramatically reduced numbers of both aerobic and anaerobic
bacteria; however, it induced a massive overgrowth of yeasts.
Piperacillin (i.v.) had similar, but less profound eﬀects
[30]. Parenterally administered ceftriaxone may also induce
Candida overgrowth in humans [31], along with intravenous
ciprofloxacin in a part of volunteers [32]. Increased presence
of yeasts in the intestinal content may be particularly
dangerous in critical illness, since Candida albicans was
reported to facilitate the translocation of Escherichia coli
through the epithelial barrier in vitro [33].
A profound change in the intestinal milieu was revealed
in patients with severe systemic inflammatory response
syndrome (SIRS). The reduced number of intestinal obligate
anaerobes in SIRS compared to normal (among these strains
Bacteroidaceae, Bifidobacterium, and Veillonella sp.) along
with a decreased occurrence of Lactobacillus was reported,
while Staphylococcus and Pseudomonas numbers increased
significantly. The total amount of organic acids (particularly
butyric acid, propionic acid, and acetic acid) was reduced
while the pHwas elevated in the intestinal content of patients
with SIRS [34]. Furthermore, an altered gut flora (a decrease
in total obligate anaerobes and an increase in pathogenic
bacteria) might be a prognostic marker in these patients
[35]. Critical illness-associated changes in the intestinal flora
may occur surprisingly rapidly, as shown by a rat model
of pancreatitis, where anaerobic bacteria and Lactobacilli
numbers in the colon and the distal small intestine decreased
from 6 to 12 hours [36]. Special nutrition protocols also
have a marked eﬀect on the composition of the intestinal
environment. Fiber-free total enteral nutrition resulted in a
decrease of anaerobic and an increase of aerobic bacteria in
the fecal flora of human subjects. Total parenteral nutrition
was shown to reduce the number of both aerobic and
anaerobic bacteria, and induced a decrease of short-chain
fatty acids compared to the fiber-free enteral nutrition group
[37].
2.3. Regulation of Bacterial Virulence. Changes of the gut
microbial flora and the intestinal microenvironment in
citically ill patients are particularly relevant considering the
mechanism of quorum sensing (QS) [29, 38]. QS is a system
for the regulation of virulence genes in bacteria that comes
into play beyond a critical bacterial density. QS molecules
provide opportunity for cell-to-cell communication in bac-
terial communities to coordinate and synchronize their
behaviour, when bacteria sense a threat of elimination under
circumstances of high density and the lack of nutrients.
In these cases, a synchronized program for overwhelming
the host may be profitable for bacteria, even considering
the presence of host immunity and antibiotics. Indeed,
mediators released from ischemic, hypoxic, or injured tissues
(such as stressed intestinal epithelia) are potent activators
of the QS system in Pseudomonas aeruginosa [29]. One
of the mediators released by this bacterium this way (2-
heptyl-4-hydroxyquinoline-N-oxide) directly suppresses the
growth of Lactobacilli sp., further enhancing the chance to
invade the host [39]. A mouse model revealed that QS
activation results in the production of PA-I lectin in P.
aeruginosa, which increases tight junctional permeability,
giving free way to the systemic dissemination of ribosylating
toxin exotoxin A, that induces a lethal septic response [29].
QS circuits were also found to activate in response to
INFγ in this bacterium, resulting in enhanced virulence,
adhesion to the epithelium and disruption of the epithelial
barrier [29, 38]. These findings may explain much of the
observed discrepancies regarding the theory of “gut as the
motor of sepsis.” The original theory was based on the
conception that bacteria translocating to the circulation
through the injured intestinal barrier in critical illness
facilitate systemic inflammatory responses and contribute
to the development of multiple organ dysfunction syn-
drome (MODS). This model was supported by the fact
that germ-free animals improved survival after hemorrhagic
shock/intestinal ischemia-reperfusion compared to controls
[40, 41]. However, the number of translocated bacteria was
not enough to induce sepsis when injected into healthy
animals, and similarly, the clinically observed amount
of lipopolysaccharide (LPS) was not suﬃcient to induce
4 ISRN Immunology
a systemic inflammatory response similar to septic states.
The presence of quorum sensing, however, may provide
an explanation how the activation of virulence genes may
endow these bacteria to induce significant changes in the host
homeostasis [29, 42].
3. Gut-Microbe Interactions and Intestinal
Barrier Function in Critical Illness
3.1. Bacterial Contribution to the Intestinal Barrier. The
intestinal barrier consists of multiple mechanisms including
mucus production, epithelial layer junctional complexes, as
well as the mucosal immune apparatus including IgA anti-
bodies along with cellular components. Under physiological
circumstances, commensal microbes actively contribute to
themaintenance of the gut barrier function throughmultiple
ways. They competitively antagonize epithelial adherence
and suppress growth of pathogenic species, induce the pro-
duction of IgA antibodies andmucus, digest macromolecules
to decrease antigenic load, and provide access to SCFAs
[9, 43]. Short-chain fatty acids were reported to serve as
nutrients for epithelial cells, regulate their growth and dif-
ferentiation, decrease the in vitro permeability of intestinal
tight junctions, and induce production of cytoprotective
heat shock protein 25 (HSP25) as well as mucin (MUC2)
[9, 16, 44–47]. The induction of protective heat shock
proteins (HSPs) was also reported directly by Bacillus subtilis
derivatives [29]. Another eﬀect of SCFAs is the induction
of ornithine-decarboxylase, the enzyme catalyzing the rate-
limiting step of polyamine synthesis. These mediators have
been demonstrated to play an important role in normal cell
growth and repair of injuries in the mucosa [48].
Under circumstances of critical illness, which alters
intestinal environment and microflora, disadvantageous mi-
crobial contribution to the barrier functions gain partic-
ular importance. Numerous bacteria or bacterial products
including enteropathogenic Escherichia coli (EPEC), Clo-
stridium diﬃcile toxins, Vibrio cholerae as well as Pseu-
domonas aeruginosa PA-I lectin were shown to increase
intestinal permeability via modulation of junctional com-
plexes in epithelial cells [9, 29]. Their exact way of action
involve multiple molecular mechanisms; however, all result
in the impairment of barrier function. Inversely, Bifido-
bacteria along with Bacillus subtilis were shown to act
advantageously on the intestinal barrier [29, 49, 50].
Beyond local eﬀects, microbial presence may also aﬀect
the gut barrier from remote tissues like lungs (however,
pneumonia-related hypoxia and septic hemodynamic dis-
turbances may contribute to these eﬀects). Intratracheal
inoculation of Pseudomonas aeruginosa was shown to induce
intestinal epithelial cell cycle arrest in a mouse model
[51], while other experiments revealed IEC apoptosis in
experimental Pseudomonas pneumonia. Bcl-2 overexpress-
ing mice improved survival in this model, but the question
of bacterial translocation was not considered to be the
predominant mechanism responsible for the survival benefit
[52]. Interestingly, Bcl-2 overexpression did not improve
survival in LPS-induced acute lung injury in mice [53].
As for Gram-positive pathogens, intratracheal inoculation
of Streptococcus pneumoniae induced MODS and intestinal
leak in mice, despite the fact that relatively low number of
bacteria gained access to the circulation. This eﬀect appeared
to be a transient change, suggesting that intestinal epithelial
apoptosis or necrosis did not occur [54]. Neither Gram-
positive (S. pneumoniae) nor Gram-negative (P. aeruginosa)
pneumonia induced apoptosis in airway epithelial cells [55].
3.2. Cellular and Molecular Mechanisms Involved in the
Alteration of Physical and Immunological Barrier Function.
Intestinal epithelial cells, intraepithelial lymphocytes, Peyer’s
patches, mesenteric lymph nodes and the lamina propria
immune apparatus are all involved in physiological immune
barrier functions in the gut. Intestinal ECs are polarized cells,
possess the ability to present antigens as nonprofessional
antigen presenting cells (APCs), and were shown to express
classical MHC I, MHC II, as well as nonclassical MHC I. The
secretion of MHC-containing, antigen-loaded microparti-
cles was also reported [56–58]. The latter mechanism may
provide information to bystander cells on the antigenic
composition of the luminal content. Intestinal intraepithelial
lymphocytes contribute to host protection both as regulators
of the inflammatory response [59] and via the induction
of mucosal repair: TCRγδ+ iIELs were reported to secrete
keratinocyte growth factor (KGF), required for restoring
intestinal epithelia [60]. However, critical illness is charac-
terized by major changes in the function of the mucosal
immune barrier. Polymicrobial sepsis as well as intestinal
ischemia-reperfusion were reported to induce a dramatic
loss of lymphocytes in the intraepithelial and lamina propria
compartments as well as in Peyer’s patches. Although critical
illness seems to aﬀect eﬀector sites more profoundly than
inductive sites, it is important to note that the number of
lymphocytes in the lamina propria recovers more quickly
than in Peyer’s patches. Increased apoptosis among iIELs
and lamina propria B cells was considered to be Fas-FasL
but not endotoxin mediated. [24, 61–63]. A mouse model
has shown that TCRγδ+ iIELs seem to play an important
role in the pathomechanism of polymicrobial sepsis, since
their percentage becomes higher within the intraepithelial
compartment of the small intestine in sepsis, and γδ−/− mice
show an increased early mortality following cecal ligation
and puncture [59].
Beyond cellular components, physical and humoral
barrier functions were also reported to be impaired in critical
illness. The production of intestinal mucus was decreased in
a rat model of trauma/hemorrhagic shock, where females
had better survival rates associated with a more eﬃcient
preservation of the gut mucus layer and the barrier function,
suggesting an important role of sexual diﬀerences [64–66].
The expression of intestinal trefoil factor 3 (TFF3), which
stabilizes the mucus layer and contributes to the repair of
mucosal injuries, was reported to decrease in a rat model
of polymicrobial sepsis, along with defensin 5 (RD-5), a
wide-spectrum antimicrobial product of Paneth cells [67].
The expression of ornithine decarboxylase, a key enzyme
of polyamine synthesis, was, however, increased in a rat
model of severe burn injury, and this process played a role
in mucosal repair [68]. IgA-mediated humoral response is
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defective in several rodent models of critical illness including
endotoxemia and burn injury, and this state associates
with an impaired function of the intestinal barrier. Human
subjects with intra-abdominal sepsis also had a reduced
IgA-mediated response [69–71], which might be associated
with enhanced apoptosis or potentially the sepsis-induced
impairment of the mucosal production of IL-5 (known from
a murine model), a cytokine that normally promotes IgA
class switch [72]. However, others demonstrated an elevated
number of IgA secreting lamina propria B cells in septic mice
[63]. Besides its well-known adverse eﬀects [73], hyperoxia
was shown to enhance barrier function in synergism with
IgA in vitro [74, 75]. Beyond immunoglobulin-mediated
protection, the epithelium itself also serves as a barrier, and
the cytokine milieu has a clear impact on the permeability of
this layer: INFγ, TNFα, high-mobility group B1 (HMGB1),
IL-2, IL-4, IL-13, and a RAGE-dependent signal increases
permeability while IL-10 and TGFβ act oppositely [76–
81]. INFγ may also mediate transcytosis of Escherichia coli
through epithelial cells in vitro via lipid raft structures
[82], which is an additional mechanism independent of
tight junctions. The excess production of NO was found
to be required for the development of enhanced intestinal
permeability after hindlimb ischemia-reperfusion or the
administration of LPS. In the latter case, the changes were
associated with the altered expression and localization of
key tight junction proteins [83, 84]. Inversely, IGF-1 was
reported to be protective via the attenuation of sepsis-
induced intestinal epithelial apoptosis in mice. Higher IGF-
1 levels were associated with reduced bacterial translocation
both in human subjects and the mouse model [85].
3.3. Impact of Some Therapeutic Eﬀorts on the Intestinal
Barrier Function. Besides microbe-host interactions, thera-
peutic eﬀorts also influence the intestinal barrier in critical
illness, although detailed experimental data are poorly avail-
able. The impact of antibiotics on the intestinal community
was mentioned above. Considering animal models, steroid
drugs seem to impair mucosal barrier function via multiple
ways. Intraperitoneal administration of dexamethasone was
found to reduce IgA production, enhance bacterial adherence
to the mucosa, and facilitate translocation of bacteria from
the intestinal lumen tomesenteric lymph nodes in nonseptic,
intact rats. In mice with severe burn injury, prednisone
facilitated the translocation of Escherichia coli to the intesti-
nal wall as well as mesenteric lymph nodes [86, 87]. In
vivo exposure to lidocaine was also associated with bacterial
translocation, along with a decreased proliferation and TH2
cytokine production of T-cells in Peyer’s patches in mice
[88]. Inversely, propofol was shown to mediate a protective
eﬀect on the gut via the reduction of intestinal permeability,
mucosal TNFα and IL-6 production, NF-κB activity, as
well as plasma endotoxin levels in rats with traumatic
brain injury [89]. Both selective COX-2 inhibition and
the administration of indomethacin (a nonselective COX
inhibitor) induced enhanced apoptosis in mesenteric lymph
nodes, and attenuated the increase of macrophages in the
mucosa and MLNs in septic rats. However, selective COX-2
inhibition was reported to decrease liver injury in a rat
model of polymicrobial sepsis [90, 91]. Vasopressor agents
like norepinephrine (NE) are widely used in themanagement
of septic shock-related hypotension. Norepinephrine dose
was in a direct correlation with lactic acidosis of the rectal
mucosa in patients with septic shock; however, it remains
obscure if the vasopressor agent istelf or a more severe shock
requiring higher NE doses is responsible for this observation
[92].
4. Interactions between the Intestinal and
Systemic Compartments in Critical Illness
The exact way how events in the altered intestinal microen-
vironment disturb host homeostasis in critical illness is
yet unknown in details; however, recent investigation has
revealed many relevant pathways. The regulation system of
bacterial virulence, which provides a coordinated program
for the impairment of the mucosal barrier and systemic
spread of bacteria/bacterial products leading to a fatal septic
response in the host, was described earlier in Section 2.
Like extraintestinal tissues, gastric and intestinal mucosa is
engaged with the ability to respond to inflammatory signals
via production of diﬀerent mediators. Endotoxemia in a
mouse model resulted in the production of IL-6 in small
intestine and colonic mucosa, which was mainly related to
enterocytes along with a few cells in the lamina propria.
IL-1β induced a similar eﬀect in the small intestine [93].
The widespread apoptosis observed in the intestinal mucosa
in critical illness might however mediate immunparalysis
via the well-known ability of apoptotic cells to induce
immunosuppression [94], in case they gain access to the
systemic compartment.
The pathogenic role of certain gut-derived products in
the development of multiple organ dysfunction syndrome
was demonstrated years ago [23]. However, the level of
C3a, IL-6, and tumor necrosis factor was nearly identical in
simultaneously collected portal and systemic blood samples
in patients with major torso trauma [95]. Similarly, portal
and systemic levels of IL-1β, TNFα, and IL-6 did not diﬀer
significantly in a rat model of polymicrobial sepsis [96]. The
gut-origin lymph was, however, demonstrated to serve as a
primary route of nonbacterial intestinal products associated
with tissue injury in a trauma/hemorrhagic shock model.
Lymph derived from the stressed intestine, which gains access
to the systemic circulation via the thoracic duct, may induce
multiple organ dysfunction syndrome (MODS) and acute
respiratory distress syndrome (ARDS), which is otherwise
called the “gut-lymph hypothesis.” The exact way how gut-
origin lymph disturbs homeostasis is yet obscure; however,
pathways involving TLR4 signalling as well as NO excess
seem to be involved. [97]. Besides gut-origin lymph, gut-
origin norepinephrine also seems to be involved in sepsis
pathophysiology. A rat model has shown that during early
sepsis, gut itself may be a relevant source of norepinephrine,
which enters the hepatic circulation via the portal vein, and
induces dysfunction of hepatocytes possibly mediated via the
upregulation of inflammatory cytokine production [98].
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5. The Impact of Nutrition Protocols on
Mucosal Immunity in Critical Illness
5.1. The Intestinal Mucosa in Total Parenteral Nutrition.
Total parenteral nutrition (TPN), which we mean here
as parenteral nutrition with the lack of enteral nutrition,
is occasionally inevitable in the management of critically
ill patients. However, associated side eﬀects on mucosal
immunity and the intestinal microenvironment are worth
an exceptional attention, considering the role of the gut in
the pathomechanism of various life-threatening states. Alter-
ation in the composition of the intestinal microflora asso-
ciated with TPN was described earlier in Section 2. Murine
experiments have shown that TPN-associated adverse
eﬀects included enhanced epithelial cell apoptosis, increased
degree of bacterial translocation from the intestinal lumen,
histologically decreased height of the villus-crypt complex,
as well as alterations in the intestinal intraepithelial lympho-
cyte population. The numbers of CD4+CD8−, CD4+CD8+,
CD8αβ+ thymus-dependent along with CD8+CD44+ mature
iIELs were found to decrease in response to total parenteral
nutrition. The cytokine profile of iIELs also changed as
the levels of IL-2 and IL-10 mRNAs decreased, inverse to
the increased expression of IL-6, INFγ, IL-4, TGFβ1, as
well as TNFα mRNAs. These changes were demonstrated
to associate rather with the lack of enteral nutrition but
not the presence of parenteral nutrition [99, 100]. Both
the lack of iIEL-derived IL-10 and the overproduction of
INFγ contributed to the decreased gut barrier function in
mice [101, 102]. TPN as well as fiber-free enteral nutrition
was demonstrated to decrease jejunal IgA and insoluble
mucin levels as well, along with the increase of intestinal
permeability and bacterial translocation in rats [103]. The
fall of lymphocyte numbers in Peyer’s patches, intraepithelial
space, and lamina propria in response to total parenteral
nutrition was also reported in a mouse model [104]. Antigen
recognition pattern changes as well, as another murine
model revealed upregulated expression of TLR4, TLR5,
TLR7, and TLR9 mRNAs in response to total parenteral
nutrition, particularly in the distal part of the small intestine
[105], which might be consequent to an altered bacterial
environment. Studies on the molecular pathways involved
in TPN-associated mucosal disturbances have demonstrated
the important role of IL-7, a critical factor for the main-
tenance of several lymphoid tissues. The production of
this cytokine by intestinal epithelial cells was found to be
impaired when mice were on TPN, which associated with
reduced number and altered phenotype of iIELs. External
supplementation of IL-7 as well as intestinal overexpression
of IL-7 restored much of these changes [106, 107].
5.2. Immunonutrition and Probiotics in Critical Illness.
Supplementation of nutrition protocols with certain im-
munomodulatory-nutrient agents may have a profound
eﬀect on mucosal immunity as demonstrated by several
animal models, and the quest for possibilities of human
clinical application has been in the focus of research.
Glutamine supplementation of total parenteral nutrition in
mice was shown to attenuate TPN-induced changes in the
intestinal mucosa. Total parenteral nutrition associated with
an impaired barrier function, decreased number of intraep-
ithelial lymphocytes, and increased INFγ but decreased IL-
10 expression in iIELs. Glutamine-supplementation of TPN
resulted in a significant preservation of the barrier function,
in which the influence on iIEL cytokine profile (prevention
in the overproduction of INFγ and decline in IL-10) may
play a role. The way how glutamine aﬀected the cytokine
production of iIEL cells was independent on the IL-7
pathway [108]. Glutamine supplementation in a TPN model
was also demonstrated to reverse the TPN-induced fall in
the intestinal and airway IgA production [109], and restored
lymphocyte numbers in the intraepithelial compartment,
lamina propria and Peyer’s patches in mice. Glycyl-L-
glutamine supplementation had similar eﬀect as glutamine
on the TPN-associated atrophy of gut-associated lymphoid
tissue [104]. Glutamine was also demonstrated to attenuate
the TPN-induced decline of IL-10 and IL-4 mRNA levels in
lipopolysaccharide- (LPS-) stimulated lamina propria cells
in mice, and the expression of these mRNAs correlated with
the amount of intestinal IgA [110]. Glutamine also helped to
maintain T-lymphocyte populations in Peyer’s patches and
the production of IgA in a rat model of polymicrobial sepsis
[111]. An “immunoenhancing” enteral diet supplemented
with L-arginine,ω-3 fatty acids, and RNA fragments in septic
but not control rats was shown to increase the production of
IL-5 and IL-6, cytokines that promote IgA immunoglobulin
class switch [72]. IL-5 was also demonstrated to be required
for an optimal T-cell-dependent activation of murine B-
1 lymphocytes. B-1 cells produce natural antibodies that
contribute to the first-line protection against infectious
agents [112–114]. Supplementation of TPN with short-
chain fatty acids was also found to have a protective eﬀect
on the intestinal mucosa via multiple mechanisms. After
massive short bowel resection in rats, SCFA supplementation
of TPN upregulated the mucosal expression of ornithine
decarboxylase as well as proglucagon mRNA levels, that
might be the way by which SCFAs facilitate intestinal adap-
tation [48]. Indeed, both polyamine synthesis catalyzed by
ODC and abundance of proglucagon derivatives were shown
to associate with an advantageous eﬀect on the intestinal
mucosa [68, 115]. SCFA supplementation was also found to
enhance ileal proglucagon mRNA expression in intact rats
subjected to TPN [116]. Bulk-forming fibers as well proved
to be worthy attention, since per os fiber supplementation
of fiber-free enteral nutrition or TPN resulted in a decreased
intestinal permeability along with a lower degree of bacterial
translocation in rats [103].
The management of intestinal dysbacteriosis associated
with critical illness includes two plausible solutions: selective
digestive decontamination (SDD) or the administration of
probiotics. Conclusions from the literature demonstrate
that the prophylactic use of SDD may reduce infections,
eminently pneumonia, as well as mortality in a mixed
population of ICU patients; however, no studies focused
specifically on severe sepsis and septic shock [117]. The
use of probiotics proved to have a protective eﬀect on
the intestinal mucosa in several animal models, eminently
rodents. In rats subjected to short bowel resection, oral
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Figure 1: Major changes in the gut mucosa under the circumstances of critical illness. Injured mucosal tissues with widespread apoptosis,
histological disorganization, and a disrupted intestinal barrier face an altered microbial flora with pathological composition and increased
virulence. Damageous products from the stressed intestine gain access to the gut lymph.
treatment with probiotics reduced bacterial translocation
from the intestinal lumen and decreased intestinal epithelial
cell apoptosis [118]. Another murine model demonstrated
that orally administered lyzozyme-modified Lactobacillus
sp. improved survival of polymicrobial sepsis, which was
associated with an increase in the bacterial clearance in
the liver. These lyzozyme-modified probiotic components
(LzMPC) were shown to cross the intestinal barrier and
get engulfed by liver macrophages. LzMPC stimulated the
in vitro production of cathelicidin-related antimicrobial
peptide (CRAMP) in these cells and potentiated their
bactericidal activity. Polymicrobial sepsis was also shown to
decrease the expression of CRAMP in the liver, which was
restored by the administration of LzMPC [119]. However, in
contrast to these animal models, data on the human clinical
application of both immunonutrition and probiotics in
critically ill patients remains controversial, furthermore,
cases of Lactobacillus sepsis in connection with probiotic
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in the pathomechanism of multiple organ dysfunction syndrome.
therapy were also reported. It is likely that the administration
of the right combination of immunoenhancing supplemen-
taries or probiotics in the right patient population at the
right time might potentially be beneficial; however, further
research is required for a better understanding of the biology
of MODS [120–123].
6. Concluding Remarks
The intestinal microbiome and mucosal tissues are inter-
twined by multiple interactions both in health and
disease. Under physiological conditions, the splanchnic
community—procaryotic and eucaryotic members hand in
hand—serves the host via several ways, only one of which
is the supply with nutrients. In the critically ill host,
however, this advantageous balance is seriously injured, as
benign commensals sensing danger rapidly switch to feared
pathogens and initiate a coordinated program to invade the
succumbed tissues. This way, the intestinal microflora may
be regarded as a “shock tissue,” and the microbiome-gut
complex as a “shock organ” in a wider sense. Pathogens,
as well as bacterial and nonbacterial damageous agents
disseminate systemically and contribute to the development
of multiple organ dysfunction syndrome. A brief summary
of these events is presented on Figures 1 and 2. Today, 25
years after the first report on the hypothesis of “gut as the
motor of multiple organ failure,” the pivotal role of the
injured intestine in the development of critical illness is still
in the focus of research. Hopefully, a better understanding of
the biology of MODS/MOF will lead to the development of
more sophisticated therapeutic tools and improved survival
of patients.
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